VBVictoria Bartle

Victoria Bartle

*This is an algorithmically generated author record based on publicly available information.

Victoria Bartle has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Public Perceptions of Multiple Long‐Term Conditions: An Analysis of Mass Observation Accounts

    by Sue Bellass, Thomas Scharf, Victoria Bartle, Avan A. Sayer, Rachel Cooper

    Introduction: The growing number of people living with two or more long‐term conditions presents challenges to medicine and society. While the terminology of ‘multiple long‐term conditions’ (MLTC) or ‘multimorbidity’ has increasingly been adopted in research, policy and clinical practice, how the public responds to ‘MLTC’ remains underexplored. Given the important implications for research inclusion and intervention uptake, we aimed to address this gap by investigating public perceptions of MLTC. Methods: Mass Observation Project respondents were invited to share their views on MLTC. We collated the five words that respondents were asked to provide when hearing the term ‘multiple long‐term health conditions’ and compared the responses of people with and without MLTC. We then reviewed each full written account and identified categories describing the different ways in which the respondents referred to MLTC. Results: Of 141 valid responses, 76 (53.9%) were written by people living with MLTC, two thirds of whom (67.1%) were aged 60 or over. Regardless of MLTC status, respondents predominantly associated MLTC with challenging embodied experiences such as pain and debilitation. We identified four types of response to ‘MLTC’: adopting, overlooking, resisting and rejecting. Around half the respondents (51.8%) adopted the construct, with 11.3% resisting or rejecting it due to concerns about its utility, incongruence with personal experience, or medicalisation of human experiences of illness. Conclusion: MLTC were predominantly associated with challenging embodied experiences, and the construct was not adopted by all respondents. Researchers, clinicians and policymakers should carefully consider how to describe the construct of MLTC in public‐facing materials to optimise research inclusion and intervention uptake. Patient or Public Contribution: Co‐author VB was a public co‐investigator within the ADMISSION Research Collaborative. VB was involved from the outset of this project, contributing to the directive design, data interpretation workshops, critical review of the draft manuscript and approval of the final version. Findings from the study have also been discussed with the ADMISSION Patient Advisory Group, a diverse group of patients and carers with lived experience of MLTC who provided advice to ADMISSION Research Collaborative researchers at regular intervals throughout the lifetime of the funding.

  • Top Cited Papers
    Open Access

    Making clinical guidelines work for people with multiple long term conditions: analysis and recommendations from review of single condition guidelines

    by Sara Pretorius, Victoria Bartle, Sue Bellass, Ella-Rose Blackburn, Helen Bold, Rachel Cooper, Heather Cordell, Felicity Evison, Ray Holding, Nicola Howe, et al.

    Objectives: To evaluate how UK guidelines for individual health conditions consider coexisting multiple long term conditions and to propose improvements to guideline development processes so that guidelines appropriately account for and consider coexisting multiple long term conditions. Design: Analysis and recommendations from review of single condition guidelines. Setting: Clinical guidelines developed by the National Institute for Health and Care Excellence (NICE), UK, 1 January 2013 to 31 December 2024. Population: 56 clinical guidelines developed by NICE covering a broad range of long term conditions. Main outcome measures: The extent to which guideline recommendations consider multiple long term conditions and coexisting conditions, distinguishing between concordant conditions (those affecting the same organ system as the index condition) and discordant conditions (those affecting different systems). Results: All but one of the NICE guidelines (n=55, 98%) included some advice on managing the index condition in the presence of coexisting conditions, and 50 (89%) guidelines offered general guidance on tailoring care. Only 11 (20%) guidelines, however, explicitly referred to multiple long term conditions, and none included a dedicated section on multiple long term conditions or how care should be adapted in this context. 19 (34%) guidelines featured sections looking at specific coexisting conditions or coexisting conditions generally. Coverage of coexisting conditions varied widely across categories of conditions, with mental health guidelines dealing with the most coexisting conditions (median 10, interquartile range (IQR) 4.5-14.75) in contrast with guidelines on cancer and eye disease covering the fewest conditions (median 3, 1-4.5; median 3, 2.25-2.75, respectively). Of the 397 possible concordant pairings, 120 (30%) were referenced, whereas of the 3859 possible discordant pairings, 259 (7%) were referenced, indicating greater coverage of same system combinations. Data on the composition of guideline committees showed wide variation in size, disciplinary diversity, inclusion of generalist clinicians (eg, general practitioners, general physicians, or others with no single specialty focus), and public contributors, although lived experience of multiple long term conditions was rarely specified. Conclusions: Despite widespread acknowledgement of coexisting or multiple long term conditions, NICE guidelines are predominantly condition specific and offer limited tailored support for the care of multiple long term conditions. Recommendations rarely considered common condition clusters or the cumulative effect of multiple long term conditions. Structured improvements, such as clearer guidance on adapting care, broader cross condition referencing, and more transparent inclusion of lived experience could enhance the relevance and usability of guidelines for clinicians managing patients with multiple long term conditions.


  • Open Access

    Public and Patient Involvement in Artificial Intelligence and Big Data Healthcare Research: An Exploration of Issues and Challenges Within the AI‐Multiply Project

    by Alexandra Thompson, Victoria Bartle, Elizabeth A. Remfry, Duncan J. Reynolds, Michael R. Barnes, Nick J. Reynolds, Barbara Hanratty

    Background: Public and patient involvement and engagement (PPIE) is intended to shape research priorities and improve relevance and impact. However, implementing PPIE in complex fields such as artificial intelligence (AI) and big data health research presents specific challenges. This study explores the issues and barriers to meaningful PPIE using the AI‐Multiply project as a case example. Methods: AI‐Multiply is a large, interdisciplinary UK‐based research project using AI and routine health data to investigate trajectories of multiple long‐term conditions and polypharmacy. PPIE was embedded across all five work packages. We used a mixed‐methods approach, drawing on CUBE framework surveys, PPIE feedback forms and impact logs to evaluate involvement. Data were analysed thematically using a ‘follow‐a‐thread’ approach to identify key issues across sources. Results: Three themes were identified: (1) differing priorities —public contributors prioritised person‐centred outcomes, while researchers focused on data‐driven healthcare metrics, often constrained by data availability; (2) movement on both sides —both researchers and contributors expressed early apprehension, but mutual trust and integration developed over time; and (3) the importance of established guidance —many issues raised echoed longstanding PPIE guidance on clarity, feedback and facilitation. Conclusion: While AI and data‐specific challenges exist, many PPIE issues in this context relate to applying existing good practice in complex projects. Strong PPIE leadership, early expectation‐setting and consistent facilitation are critical for success. Findings will inform the development of practical tools to support involvement in data‐driven research. Patient or Public Contribution: Public contributors with lived experience of multiple long‐term conditions contributed to the interpretation of data and co‐authored this manuscript.


  • Open Access

    Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial

    by Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger, Chrissie Butcher, Thomas Chadwick, Emily Clare, Paul Courtney, Lyndsey Dixon, et al.

    Background: There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients. Objectives: Primary: to evaluate the clinical effectiveness of pramipexole versus placebo alongside routine mood-stabilising medications over 12 weeks in patients with treatment-resistant bipolar depression. Secondary: evaluate the impact of pramipexole on mood and anxiety, psychosocial function, cost-effectiveness, and safety and tolerability over 48 weeks. Design: Multicentre, randomised, placebo-controlled trial of pramipexole versus placebo in addition to standard-of-care mood stabilisers. Clinicians, researchers and participants were blinded throughout the duration of the study. Pre-randomisation stage (to adjust antipsychotics or commence mood stabilisers where required) before randomisation. Weekly online assessments of mood and anxiety from randomisation to week 52, with psychosocial function, quality of life and healthcare resource utilisation assessments conducted at regular intervals. Setting: Twenty-one National Health Service trusts and Health Boards across England and Scotland. Participants: Patients aged 18 years and over with a diagnosis of treatment-resistant bipolar depression currently under secondary care mental health services. Aim to randomise 290 participants. Interventions: Pramipexole or matched placebo orally once daily, titrated from 0.25 mg to maximum of 2.5 mg (salt weight) depending on efficacy and tolerability. Main outcome measures: Depression – Quick Inventory for Depressive Symptomology; anxiety – Generalised Anxiety Disorder-7-item scale; psychosocial functioning – Work and Social Adjustment Scale; hypomania/mania – Altman Self-rating Scale of Mania; tolerability – Treatment Satisfaction Questionnaire for Medication; well-being and quality of life – EuroQol-5 Dimensions, five-level version, ICEpop CAPability measure for Adults and Oxford CAPabilities questionnaire-Mental Health tools. Results: Thirty-nine participants randomised (18 to pramipexole and 21 to placebo) with 36 providing data for the primary analysis. Pramipexole led to greater reductions in depressive symptoms at 12 weeks compared to placebo [4.4 (4.8) vs. 2.1 (5.1)]: a medium-sized (d = −0.72) but not statistically significant difference (95% confidence interval −0.4 to 6.3; p = 0.087). There were some statistically significant positive effects of pramipexole on secondary outcomes (reduction in depressive symptoms at 36 weeks, response and remission rates at trial exit, psychosocial function). Pramipexole was associated with an increased rate of hypomania/manic symptoms, but this appeared to be reduced by coadministration with an antipsychotic. General tolerability of pramipexole was good. There were significant annual gains in health-related quality of life and capability-well-being and tendency towards reduced health and social care costs. Limitations: Small sample size and variable follow-up period due to recruitment during COVID-19 pandemic and the trial closing early. Participants limited to those in secondary care mental health services. All assessments only available in English. Conclusions: No change in clinical practice can be recommended as there was not a significant difference between pramipexole and placebo on the primary efficacy outcome measure. However, there was evidence of positive effects of pramipexole on mood, psychosocial function and quality of life. Future work: Replication in a larger population and research to investigate the impact of coadministration of antipsychotics alongside pramipexole. Trial registration: This trial is registered as ISRCTN72151939 and EudraCT 2018-2869-18. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/154/01) and is published in full in Health Technology Assessment; Vol. 29, No. 21. See the NIHR Funding and Awards website for further award information.